Free Trial
NASDAQ:HCM

HUTCHMED (HCM) Stock Price, News & Analysis

HUTCHMED logo
$13.86 -0.52 (-3.62%)
As of 09:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About HUTCHMED Stock (NASDAQ:HCM)

Key Stats

Today's Range
$13.84
$14.05
50-Day Range
$11.81
$16.75
52-Week Range
$11.51
$21.92
Volume
3,439 shs
Average Volume
108,012 shs
Market Capitalization
$2.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00
Consensus Rating
Hold

Company Overview

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Remove Ads

HUTCHMED Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

HCM MarketRank™: 

HUTCHMED scored higher than 46% of companies evaluated by MarketBeat, and ranked 635th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    HUTCHMED has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    HUTCHMED has received no research coverage in the past 90 days.

  • Read more about HUTCHMED's stock forecast and price target.
  • Earnings Growth

    Earnings for HUTCHMED are expected to grow by 812.50% in the coming year, from $0.16 to $1.46 per share.

  • Price to Book Value per Share Ratio

    HUTCHMED has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about HUTCHMED's valuation and earnings.
  • Percentage of Shares Shorted

    0.21% of the float of HUTCHMED has been sold short.
  • Short Interest Ratio / Days to Cover

    HUTCHMED has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in HUTCHMED has recently increased by 0.81%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    HUTCHMED does not currently pay a dividend.

  • Dividend Growth

    HUTCHMED does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.21% of the float of HUTCHMED has been sold short.
  • Short Interest Ratio / Days to Cover

    HUTCHMED has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in HUTCHMED has recently increased by 0.81%, indicating that investor sentiment is decreasing.
  • News Sentiment

    HUTCHMED has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for HUTCHMED this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    1 people have added HUTCHMED to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, HUTCHMED insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.60% of the stock of HUTCHMED is held by insiders.

  • Percentage Held by Institutions

    Only 8.82% of the stock of HUTCHMED is held by institutions.

  • Read more about HUTCHMED's insider trading history.
Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

HCM Stock News Headlines

The Crypto Market is About to Change Lives
I've discovered something so significant about the 2025 crypto market that I had to put everything else aside and write a book about it. This isn't just another Bitcoin prediction – it's a complete roadmap for what I believe will be the biggest wealth-building opportunity of this decade. The evidence is so compelling, I'm doing something that probably seems insane: I'm giving away my entire book for free.
Hutchmed says NDA for Tazverik granted conditional approval in China
See More Headlines

HCM Stock Analysis - Frequently Asked Questions

HUTCHMED's stock was trading at $14.41 at the beginning of the year. Since then, HCM stock has decreased by 4.0% and is now trading at $13.84.
View the best growth stocks for 2025 here
.

HUTCHMED (HCM) raised $100 million in an IPO on Thursday, March 17th 2016. The company issued 6,100,000 shares at $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

HUTCHMED's top institutional investors include Hennion & Walsh Asset Management Inc. (0.03%) and Rhumbline Advisers.

Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), General Electric (GE) and ServiceNow (NOW).

Company Calendar

Today
4/16/2025
Next Earnings (Estimated)
5/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HCM
Employees
1,988
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$19.00
High Stock Price Target
$19.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+37.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$630.20 million
Cash Flow
$0.56 per share
Price / Cash Flow
24.51
Book Value
$4.27 per share
Price / Book
3.24

Miscellaneous

Free Float
168,044,000
Market Cap
$2.41 billion
Optionable
Not Optionable
Beta
0.66

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:HCM) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners